

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

In re application of:

GEORGIEV *et al.*

Appl. No. 09/462,625

§102(e) Date: July 28, 2000



Art Unit: 1646

Examiner: To Be Assigned

Atty. Docket: 0652.1630001/EKS/TBB

For: **Tumor Growth Inhibition- and Apoptosis-
Associated Genes and Polypeptides and
Methods of Use Thereof**

RECEIVED

FEB 06 2001

Request for Corrected Official Filing Receipt

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

*Attn: Office of Initial Patent
Examination's Customer
Service Center*

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:

In the Continuing Data as Claimed by Applicant section, please insert the following:
**--AND CLAIMS THE BENEFIT OF U.S. APPLICATION NO. 08/893,764
07/11/1997--.**

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Eric K. Steffe

Attorney for Applicants

Registration No. 36,688

Date: 11/21/00
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

FILING RECEIPT



OC00000005354103




**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/462,625	07/28/2000	1646	2388	0652,630,004	26	67	

STERNE KESSLER GOLDSTEIN & FOX
1100 NEW YORK AVENUE NW
SUITE 600
WASHINGTON, DC 200053934



RECEIVED

FEB 06 2001

TECH CENTER 1600/2900

Date Mailed: 08/25/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

GEORGII GEORGIEV, MOSCOW, RUSSIAN FEDERATION;
SERGEI KISELEV, MOSCOW, RUSSIAN FEDERATION;
EGOR PROKHORCHOUK, MOSCOW, RUSSIAN FEDERATION;
ELINBORG OSTERMANN, VIENNA, AUSTRIA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/EP98/04287 07/10/1998
AND CLAIMS THE BENEFIT OF

Foreign Applications U.S. APPLICATION NO. 08/893,764
07/11/1997


If Required, Foreign Filing License Granted 08/25/2000

Title

TUMOR GROWTH INHIBITION- AND APOPTOSIS-ASSOCIATED GENES AND POLYPEPTIDES
AND METHODS OF USE THEREOF

Preliminary Class

514



Data entry by : BARRETO, NGA

Team : OIPE

Date: 08/25/2000



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

SERIAL NUMBER 09/462,625	FILING DATE 07/28/2000 RULE -	CLASS 514	GROUP ART UNIT 1646 <i>SR</i> <i>1642</i>	ATTORNEY DOCKET NO. 0652.1630001	
APPLICANTS GEORGII GEORGIEV, MOSCOW, RUSSIAN FEDERATION; SERGEI KISELEV, MOSCOW, RUSSIAN FEDERATION; EGOR PROKHORCHOUK, MOSCOW, RUSSIAN FEDERATION; ELINBORG OSTERMANN, VIENNA, AUSTRALIA;					
** CONTINUING DATA ***** THIS APPLICATION IS A 371 OF PCT/EP98/04287 07/10/1998 WHICH CLAIMS BENEFIT OF 08/893,764 07/11/1997 PAT 6,172,211 <i>SR</i>					
** FOREIGN APPLICATIONS ***** <i>SR</i>					
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 08/25/2000					
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after allowance Verified and Acknowledged <i>SR</i> Examiner's Signature Initials		STATE OR COUNTRY RUSSIAN FEDERATION	SHEETS DRAWING 26	TOTAL CLAIMS 67	INDEPENDENT CLAIMS 7
ADDRESS STERNE KESSLER GOLDSTEIN & FOX 1100 NEW YORK AVENUE NW SUITE 600 WASHINGTON ,DC 200053934					
TITLE TUMOR GROWTH INHIBITION- AND APOPTOSIS-ASSOCIATED GENES AND POLYPEPTIDES AND METHODS OF USE THEREOF					
FILING FEE RECEIVED 2388	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		

FILE COPY

RECEIVED

FEB 06 2001

TECH CENTER 1600/2900